PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Saini, M. ; Schmidleitner, L. ; Moreno, H.D.* ; Donato, E.* ; Falcone, M.* ; Bartsch, J. ; Klein, C.* ; Vogel, V.* ; Würth, R.* ; Pfarr, N.* ; Espinet, E.* ; Lehmann, M. ; Königshoff, M. ; Reitberger, M.* ; Haas, S.* ; Graf, E. ; Schwarzmayr, T. ; Strom, T.M. ; Spaich, S.* ; Sütterlin, M.* ; Schneeweiss, A.* ; Weichert, W.* ; Schotta, G.* ; Reichert, M.* ; Aceto, N.* ; Sprick, M.R.* ; Trumpp, A.* ; Scheel, C.

Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancer.

Cell Rep. 42:112533 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The acquisition of mesenchymal traits is considered a hallmark of breast cancer progression. However, the functional relevance of epithelial-to-mesenchymal transition (EMT) remains controversial and context dependent. Here, we isolate epithelial and mesenchymal populations from human breast cancer metastatic biopsies and assess their functional potential in vivo. Strikingly, progressively decreasing epithelial cell adhesion molecule (EPCAM) levels correlate with declining disease propagation. Mechanistically, we find that persistent EPCAM expression marks epithelial clones that resist EMT induction and propagate competitively. In contrast, loss of EPCAM defines clones arrested in a mesenchymal state, with concomitant suppression of tumorigenicity and metastatic potential. This dichotomy results from distinct clonal trajectories impacting global epigenetic programs that are determined by the interplay between human ZEB1 and its target GRHL2. Collectively, our results indicate that susceptibility to irreversible EMT restrains clonal propagation, whereas resistance to mesenchymal reprogramming sustains disease spread in multiple models of human metastatic breast cancer, including patient-derived cells in vivo.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
8.800
0.000
3
1
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Cp: Cancer ; Emt ; Epcam ; Grhl2 ; Zeb1 ; Breast Cancer ; Intratumor Heterogeneity ; Metastasis; Tumor-initiating Cells; Feedback Loop; Stem-cell; Lung Metastasis; E-cadherin; Emt; Transition; Plasticity; Chromatin; Zeb1
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 2211-1247
e-ISSN 2211-1247
Zeitschrift Cell Reports
Quellenangaben Band: 42, Heft: 6, Seiten: , Artikelnummer: 112533 Supplement: ,
Verlag Cell Press
Verlagsort 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Stem Cell Research (ISF)
Institute of Lung Health and Immunity (LHI)
Institute of Human Genetics (IHG)
POF Topic(s) 30204 - Cell Programming and Repair
80000 - German Center for Lung Research
30202 - Environmental Health
30501 - Systemic Analysis of Genetic and Environmental Factors that Impact Health
Forschungsfeld(er) Stem Cell and Neuroscience
Lung Research
Genetics and Epidemiology
PSP-Element(e) G-500890-001
G-501800-803
G-503100-001
G-500700-001
Förderungen Swiss Bridge Award
Dietmar Hopp Foundation
Max Eder Grant of the German Cancer Aid Organisation (Deutsche Kreb-shilfe)
German Cancer Aid Organisation (Max-Eder Program)
German Research Foundation (DFG)
Federal Ministry of Education and Research, SATURN3 "Spatial and Temporal Resolution of Intratumoral Heterogeneity in 3 hard-to-treat Cancers
Deutsche Forschungsgemeinschaft (DFG
German Cancer Aid Organisation (Translational Oncology Program)
German Research Foundation)
European Research Council
ETH Zurich
strategic focus area of Personalized Health and Related Technologies at ETH Zurich
Future and Emerging Technologies programme of the European Commission
Swiss National Science Foundation
Swiss Cancer League
ETH Lymphoma Challenge
DOI 10.1016/j.celrep.2023.112533
WOS ID 001034905400001
Scopus ID 85160792198
PubMed ID 37257449
Erfassungsdatum 2023-10-06
[➜Korrektur melden]